Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.48)
# 313
Out of 5,105 analysts
234
Total ratings
46.95%
Success rate
30.47%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $13.00 | +84.62% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $9.77 | +94.47% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $8.33 | +188.12% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $40.78 | -6.82% | 9 | Nov 5, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $132 → $153 | $91.85 | +66.58% | 9 | Oct 17, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $47.16 | +33.59% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $19.51 | +310.05% | 10 | Sep 25, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $36.23 | +189.82% | 20 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $118 | $75.64 | +56.00% | 21 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Overweight | $74 | $74.61 | -0.81% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $11 | $6.27 | +75.44% | 1 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $5.87 | +172.57% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $26.02 | +15.30% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $21.53 | +276.22% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $5.79 | +20.90% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $52.00 | +136.54% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.91 | +2,201.79% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.17 | +222.58% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $19.78 | +26.39% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $27.51 | +143.55% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $10.55 | +99.05% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $6.21 | +173.75% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.85 | +107.79% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.67 | +558.68% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.36 | +235.82% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.09 | +1,184.40% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.31 | +892.37% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.51 | +1,290.73% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.66 | +261.45% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.98 | +910.10% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $5.05 | +355.45% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.20 | +75,213.81% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $32.00 | +1,150.00% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $1.94 | +4,281.44% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.62 | +2,619.03% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $2.22 | +8,008.11% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.36 | +708.82% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.47 | +3,981.63% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.08 | +8,233.33% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.05 | +239,900.00% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $2.28 | +133,233.33% | 1 | Jan 9, 2020 |
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $13.00
Upside: +84.62%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $9.77
Upside: +94.47%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $8.33
Upside: +188.12%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $40.78
Upside: -6.82%
Disc Medicine
Oct 17, 2025
Maintains: Overweight
Price Target: $132 → $153
Current: $91.85
Upside: +66.58%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $47.16
Upside: +33.59%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $19.51
Upside: +310.05%
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $36.23
Upside: +189.82%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $75.64
Upside: +56.00%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $74.61
Upside: -0.81%
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $6.27
Upside: +75.44%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.87
Upside: +172.57%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $26.02
Upside: +15.30%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $21.53
Upside: +276.22%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $5.79
Upside: +20.90%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $52.00
Upside: +136.54%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.91
Upside: +2,201.79%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.17
Upside: +222.58%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $19.78
Upside: +26.39%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $27.51
Upside: +143.55%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $10.55
Upside: +99.05%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $6.21
Upside: +173.75%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $3.85
Upside: +107.79%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.67
Upside: +558.68%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.36
Upside: +235.82%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.09
Upside: +1,184.40%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.31
Upside: +892.37%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.51
Upside: +1,290.73%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.66
Upside: +261.45%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.98
Upside: +910.10%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $5.05
Upside: +355.45%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.20
Upside: +75,213.81%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $32.00
Upside: +1,150.00%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.94
Upside: +4,281.44%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.62
Upside: +2,619.03%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $2.22
Upside: +8,008.11%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.36
Upside: +708.82%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.47
Upside: +3,981.63%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.08
Upside: +8,233.33%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.05
Upside: +239,900.00%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $2.28
Upside: +133,233.33%